Patent Expirations
3 articles on Patent Expirations, written by Shotlee and medically reviewed for clinical accuracy.
Ozempic Goes Generic Worldwide, But Not in U.S. Until 2030
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
5 min read
Semaglutide Could Cost as Little as $28/Year by End of 2026
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
5 min read
Semaglutide Production Cost: $3/Month Could Expand Access to Obesity & Diabet...
A new analysis shows semaglutide, the key ingredient in Ozempic and Wegovy, can be produced for just $3 per month. As patents expire in countries like Brazil, China, and India, generics could dramatically boost access to obesity and diabetes treatments worldwide. This development offers hope amid rising global rates of these conditions.
5 min read